Sequoia Capital Israel

Danatlas is a pharmaceutical company that develops drugs designed for oncology treatment. It also provides drug research and development in the fields of cancer, inflammation, blood, and metabolic diseases.

Generation Lab aims to enhance human health by developing the first clinically applicable test that assesses an individual's biological age progression and disease risk. This enables longer, healthier lives.

Full-Life Technologies specializes in developing and commercializing radiopharmaceuticals for cancer therapy. It offers research and development, production, and distribution services within the radiotherapy sector, aiming to enhance patient outcomes through innovative nuclear medicine solutions.

Wuhan Neurophth Biotechnology Co., Ltd. is a pioneering ophthalmology gene drug research and development company based in Wuhan, China, established in 2008. It focuses on gene therapies for ocular genetic diseases, with a particular emphasis on Leber hereditary optic neuropathy (LHON), a condition caused by genetic mutations. Neurophth has made significant advancements in the field, completing the world's first clinical study of gene therapy for LHON in 2011, which involved nine patients and has since observed their progress over seven years. The company aims to develop effective treatments for various ophthalmic disorders, including degenerative optic nerve injuries and vascular retinopathy, thereby providing physicians with innovative therapeutic options for patients suffering from these conditions.

Danatlas is a pharmaceutical company that develops drugs designed for oncology treatment. It also provides drug research and development in the fields of cancer, inflammation, blood, and metabolic diseases.

MoleculeMind is an AI-driven protein design platform focused on revolutionizing protein discovery, optimization, and design. The company utilizes advanced AI algorithms to enhance the drug development process and has applications across various sectors, including industrial production, agriculture, material design, and environmental improvement. MoleculeMind offers an integrated biological computing platform that enables the prediction and design of peptides, antibodies, enzymes, and small proteins, facilitating industrial-scale protein optimization and design for diverse research and application needs.

PhaBuilder is a technology-driven company established in February 2021 by Professor Guoqiang Chen, specializing in synthetic biology with a focus on the engineering application of halophilic microbes. The company employs advanced techniques in Next Generation Industrial Biotechnology to create high-value products such as biodegradable polyhydroxyalkanoates (PHA), ectoine, and cadaverine, targeting multiple sectors, including materials and pharmaceuticals. PhaBuilder is currently constructing two PHA production facilities in China and aims to establish 3-5 large-scale production sites within five years. The company utilizes an interdisciplinary approach that combines biology, engineering, and information technology to transform genetic programs, thereby offering sustainable solutions across diverse fields. With significant backing from notable investors, PhaBuilder is dedicated to integrating synthetic biotechnology into everyday life and advancing intelligent biological manufacturing, with the overarching goal of fostering a greener future through microbial innovation.

Rhegen is engaged in the research and development of mRNA medicine and gene therapy, focusing on synthetic biology technologies to create innovative mRNA drugs and vaccines. The company specializes in platform technologies essential for nucleic acid therapeutics, including mRNA design, synthesis, and non-carrier delivery methods. Rhegen applies these advancements to drug research and development, targeting various clinical indications such as functional protein defects, cancer, and infectious diseases. With a commitment to enhancing drug synthesis and developing novel drug targets, Rhegen aims to contribute significantly to the field of therapeutics, emphasizing both market potential and clinical value.

Biosysen operates as a synthetic biology company specializing in species design. It employs software engineering principles to enhance biological productivity through self-replicating, scalable systems. The company's core offerings include artificial species libraries and associated pipelines tailored to specific industrial needs, with a focus on food, daily chemicals, and protein drug research and development.

Frontera Therapeutics is a biotechnology company dedicated to developing and commercializing recombinant virus-based gene therapies. Its mission is to establish an affordable and scalable platform for producing high-quality rAAV therapies, targeting genetic disorders such as those affecting the eye, liver, metabolism, and neuromuscular systems.

Full-Life Technologies specializes in developing and commercializing radiopharmaceuticals for cancer therapy. It offers research and development, production, and distribution services within the radiotherapy sector, aiming to enhance patient outcomes through innovative nuclear medicine solutions.

Bioforany is a biocatalyst manufacturer focused on the development and sale of innovative biocatalysts for various industries. The company produces a range of products, including chiral alcohols, chiral amines, chiral hydroxy acids, amino acids, chiral epoxides, lipases, oxidoreductases, and epoxidases. Utilizing advanced green biomanufacturing technology, Bioforany offers low-carbon solutions that cater to multiple sectors, such as pharmaceutical intermediates, traditional Chinese medicine decoction components, functional food, animal nutrition, daily chemical care, plant protection, and renewable materials.

MoleculeMind is an AI-driven protein design platform focused on revolutionizing protein discovery, optimization, and design. The company utilizes advanced AI algorithms to enhance the drug development process and has applications across various sectors, including industrial production, agriculture, material design, and environmental improvement. MoleculeMind offers an integrated biological computing platform that enables the prediction and design of peptides, antibodies, enzymes, and small proteins, facilitating industrial-scale protein optimization and design for diverse research and application needs.

Jitai Medicine (METiS) is a biotechnology company that uses artificial intelligence to drive drug delivery and drug discovery. It combines advanced technologies like artificial intelligence, machine learning, and quantum simulation to achieve more effective design of innovative delivery materials, drug candidate selection and formulation design, "programmable nucleic acid drug" development, and nucleic acid delivery design.

Grit Science is a biotechnology company specializing in gene therapeutics, focusing on the research and development of liver-related genetic treatments. The firm is dedicated to creating innovative medical products that address clinical needs and enhance human health. Through its commitment to advancing biopharmaceutical technology, Grit Science aims to provide effective solutions in the field of genetic medicine.

HemaCell is a biotechnology company specializing in cell therapy, specifically focused on regenerating hematopoietic lineages, which include blood and immune cells, through advanced in vitro techniques. Leveraging innovative stem cell reprogramming, editing, and differentiation technologies, HemaCell aims to address the critical shortage of platelets necessary for treating various diseases such as cancer, liver disease, critical illness, and hematological disorders. The company employs a unique platform that utilizes platelets as drug delivery carriers, facilitating the rapid establishment of induced pluripotent stem cells (iPSCs) and gene targeting technologies. In addition to platelet production, HemaCell is dedicated to developing novel therapeutic solutions for diseases associated with platelet abnormalities, thereby offering effective treatment options and addressing significant medical needs.

PhaBuilder is a technology-driven company established in February 2021 by Professor Guoqiang Chen, specializing in synthetic biology with a focus on the engineering application of halophilic microbes. The company employs advanced techniques in Next Generation Industrial Biotechnology to create high-value products such as biodegradable polyhydroxyalkanoates (PHA), ectoine, and cadaverine, targeting multiple sectors, including materials and pharmaceuticals. PhaBuilder is currently constructing two PHA production facilities in China and aims to establish 3-5 large-scale production sites within five years. The company utilizes an interdisciplinary approach that combines biology, engineering, and information technology to transform genetic programs, thereby offering sustainable solutions across diverse fields. With significant backing from notable investors, PhaBuilder is dedicated to integrating synthetic biotechnology into everyday life and advancing intelligent biological manufacturing, with the overarching goal of fostering a greener future through microbial innovation.

Vibrant develops an AI drug development platform to focus on building immune system-related drug pipelines. The company will use artificial intelligence algorithms to accelerate the efficiency of drug development in various aspects such as target discovery, drug design, and drug efficacy evaluation; at the same time, the company expects to continuously improve the success rate of drug development through sustainable data accumulation and algorithm optimization. It was founded and headed by Dr. Wang Luquan and is based in Guangzhou, Guangdong, China.

Jitai Medicine (METiS) is a biotechnology company that uses artificial intelligence to drive drug delivery and drug discovery. It combines advanced technologies like artificial intelligence, machine learning, and quantum simulation to achieve more effective design of innovative delivery materials, drug candidate selection and formulation design, "programmable nucleic acid drug" development, and nucleic acid delivery design.

Shanghai Duoning Biotechnology Co., Ltd. specializes in the development of serum-free, personalized, and chemically defined cell culture media for the biopharmaceutical industry. Founded in 2005 and based in Shanghai, the company offers a range of products, including basic media, feed media, and cell therapy media. Duoning Biotech is dedicated to providing tailored media development, cell culture process optimization, and commissioned formula production services, utilizing its expertise in animal cell culture concepts. The company supports the research, development, and commercialization of biologics products by delivering comprehensive solutions that encompass technical support and customized services tailored to the needs of pharmaceutical and scientific research institutions.

Wuhan Neurophth Biotechnology Co., Ltd. is a pioneering ophthalmology gene drug research and development company based in Wuhan, China, established in 2008. It focuses on gene therapies for ocular genetic diseases, with a particular emphasis on Leber hereditary optic neuropathy (LHON), a condition caused by genetic mutations. Neurophth has made significant advancements in the field, completing the world's first clinical study of gene therapy for LHON in 2011, which involved nine patients and has since observed their progress over seven years. The company aims to develop effective treatments for various ophthalmic disorders, including degenerative optic nerve injuries and vascular retinopathy, thereby providing physicians with innovative therapeutic options for patients suffering from these conditions.

ComGen Pharma is a biotechnology company that specializes in the research and development of innovative therapeutic drugs targeting the complement system. The company aims to create effective immunotherapies for autoimmune diseases and tumors by focusing on new and key targets within this biological pathway. Recently, ComGen Pharma secured nearly 100 million yuan in financing, which will primarily support phase I clinical trials for its complement inhibitors, advance its drug pipeline, and enhance its innovative drug research and development platform. The financing round was led by prominent investors, including Sequoia China and Yahui Investment, with additional support from Fuchuang Investment and Renyou Investment.

Structure Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing oral small-molecule medicines for chronic diseases with high unmet medical needs. Its platform combines structure-based drug design, computational chemistry, and data integration to create orally available therapies that overcome limitations of biologics and peptide drugs. The company concentrates on targeting G-protein coupled receptors and other mechanisms, leveraging structural insights to identify differentiated, efficacious, and safe treatments. Its programs address cardiovascular, metabolic, and pulmonary conditions, with a focus on delivering convenient, effective medicines that can offer broad patient impact and commercial potential. Structure Therapeutics conducts its research and development activities across its pipeline within a single organization and seeks to advance clinical candidates through development.

Cellular Biomedicine Group, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for cancer and stem cell therapies for degenerative diseases in Greater China. The company employs proprietary cell-based technologies, including various forms of CAR-T therapy, which targets different cancer types, and human adipose-derived mesenchymal progenitor cells aimed at treating joint diseases. Its product pipeline features therapies such as CD20 and CD22 CAR-T for B cell malignancies, and alpha fetoprotein TCR-T targeting hepatocellular carcinoma. Additionally, Cellular Biomedicine is developing knee osteoarthritis treatments, including AlloJoin and Re-Join, the latter having completed Phase IIb trials. The company also engages in broader biopharmaceutical activities, encompassing research and development, technical support, and manufacturing of pharmaceutical polypeptides and medical devices. It has established a partnership with Novartis Pharma AG to produce and supply the CAR-T cell therapy Kymriah in China. Founded in 2001, Cellular Biomedicine Group is headquartered in New York, New York, and draws on a wealth of cellular medicine research and expertise from scientists and clinicians across the United States, England, and China.

Metware is a developer of advanced medical metabolic technology, focusing on metabolomics to enhance life science research and clinical applications. The company specializes in metabolism analysis and testing services, targeting areas such as cancer, metabolic disorders, and infectious diseases. By leveraging innovative metabolism technology, Metware aims to provide effective data analysis that supports patients and facilitates improved treatment options in the medical field.

XtalPi is a pharmaceutical technology company that applies quantum mechanics, artificial intelligence, and high-performance computing to accelerate drug discovery and development. Its Intelligent Digital Drug Discovery and Development platform weaves physics-based modeling with AI to increase efficiency, accuracy, and success rates at critical stages of R&D. The company offers tools for crystal structure prediction and determination, solid-state testing and analysis, and crystallization process development, as well as solid-state screening and evaluation, enabling faster optimization of drug candidates. XtalPi also provides drug design support for small molecules and collaboration options in antibody and peptide research, and offers platform-based AI model development and integration across pharmaceutical workflows. Founded in 2014, it is based in Cambridge, Massachusetts, with additional offices in China.

Shanghai Anovent Pharmaceutical Co., Ltd., founded in 2017 and headquartered in Shanghai, China, specializes in the development of high-quality inhalation medicines tailored for hospitals and medical institutions. The company focuses on offering safe and affordable pharmaceutical products, which include both generic and specialized inhalation therapies. By providing these medications, Anovent aims to enhance the quality of medical treatment available to patients in healthcare settings.

Joyo Pharma focuses on the research and development of drugs for the treatment of tumors, autoimmunity, metabolism, and infectious diseases.

PhaBuilder is a technology-driven company established in February 2021 by Professor Guoqiang Chen, specializing in synthetic biology with a focus on the engineering application of halophilic microbes. The company employs advanced techniques in Next Generation Industrial Biotechnology to create high-value products such as biodegradable polyhydroxyalkanoates (PHA), ectoine, and cadaverine, targeting multiple sectors, including materials and pharmaceuticals. PhaBuilder is currently constructing two PHA production facilities in China and aims to establish 3-5 large-scale production sites within five years. The company utilizes an interdisciplinary approach that combines biology, engineering, and information technology to transform genetic programs, thereby offering sustainable solutions across diverse fields. With significant backing from notable investors, PhaBuilder is dedicated to integrating synthetic biotechnology into everyday life and advancing intelligent biological manufacturing, with the overarching goal of fostering a greener future through microbial innovation.

dMed Company Limited, also known as dMed Biopharmaceutical Co., Ltd., is a clinical contract research organization based in Shanghai, China. Established in 2016, dMed specializes in offering a comprehensive range of services to support the development of medicines and medical devices. Its offerings include consulting, clinical operations, biostatistics and programming, data management, pharmacovigilance, clinical science and medical affairs, quality assurance, and regulatory affairs and strategy. The company serves a diverse clientele, including biopharmaceutical and medical device companies, and aims to establish itself as a prominent international brand in the field of drug innovation services and solutions.

neoX Biotech is a Beijing-based biotechnology company founded in 2018 that specializes in the development of antigen-based cancer vaccines. By integrating artificial intelligence with biophysics, neoX Biotech focuses on the discovery and development of macromolecular and multispecific drugs, primarily in the field of immuno-oncology. The company has established a platform for early therapeutic discovery, which includes neoantigen prediction and T cell receptor screening, as well as the characterization of protein-protein interactions. This innovative approach aims to provide effective treatments for cancer patients by advancing drug research and development.

Biosysen operates as a synthetic biology company specializing in species design. It employs software engineering principles to enhance biological productivity through self-replicating, scalable systems. The company's core offerings include artificial species libraries and associated pipelines tailored to specific industrial needs, with a focus on food, daily chemicals, and protein drug research and development.

MoonBiotech is a biotechnology company focused on the commercialization of microbial resources.

Insilico Medicine, Inc. is a biotechnology company that leverages artificial intelligence (AI) to transform drug discovery, biomarker development, and aging research. Founded in 2014 and based in Baltimore, Maryland, the company has established itself as a pioneer in applying advanced AI techniques, such as generative adversarial networks and reinforcement learning, to create novel molecular structures for various diseases, including cancer and age-related conditions. Insilico Medicine operates an integrated platform that covers all stages of drug discovery, from initial research to clinical trial analysis. Its projects include Pharma.AI, which offers machine learning services to various sectors, and Young.AI, a platform focused on aging predictors. The company also pursues internal drug discovery initiatives targeting diseases like Alzheimer's and Parkinson's, and has partnered with Life Extension to produce nutraceutical products utilizing deep learning and bioinformatics. Additionally, Insilico Medicine provides consumer applications aimed at enhancing health and longevity.

Stemirna Therapeutics is a RNA technology based drug development company designed to maximize the potential of RNA science. The company currently has more than a dozen of independently-developed mRNA drug projects, focusing on the fields of mRNA-based personalized cancer vaccines, mRNA vaccines for infectious disease, protein defects diseases, and genetic diseases, providing cure and solutions for cancer and infectious diseases, better serving patients.

Analytical Biosciences is a developer of single-cell genomics focused on creating precise maps of human diseases. The company collaborates with medical research institutions, hospitals, and pharmaceutical firms to leverage single-cell genomics and bioinformatics for improving disease diagnosis and treatment. By conducting large-scale systematic mapping of diseases at the single-cell level, Analytical Biosciences engages in extensive data mining to support its partners in discovering new therapeutic targets and developing innovative treatment strategies. Utilizing high-resolution databases and advanced data analytics, the company aims to unlock disease mechanisms and facilitate the identification and validation of novel cellular targets and biomarkers. This approach positions Analytical Biosciences at the forefront of advancing next-generation therapeutics and diagnostics.

Phanes Therapeutics is a biotechnology company specializing in drug discovery for immuno-oncology and eye diseases. Established in 2016, the company focuses on developing monoclonal antibodies for solid tumors and conditions like age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. Additionally, they work on bispecific antibodies targeting small cell lung cancer.

EdiGene Inc. is a biotechnology company specializing in the development of genome editing technologies for therapeutic applications in cancer and various genetic diseases. Founded in 2015 and headquartered in Beijing, China, with additional offices in Guangzhou and Cambridge, Massachusetts, EdiGene focuses on both ex vivo and in vivo gene-editing therapies. The company has established proprietary platforms for editing hematopoietic stem cells and T cells, as well as an RNA base editing approach for in vivo applications. EdiGene's innovative methods enable targeted modifications of genetic information in human cells and facilitate high-throughput drug discovery through advanced screening techniques. By translating these technologies into novel therapeutics, EdiGene aims to improve the safety and efficacy of gene therapy, ultimately benefiting patients, the pharmaceutical industry, and the scientific research community.

VivaVision Biotech is a clinical-stage R&D biopharmaceutical company that is developing novel medicines to treat topical diseases. VivaVision Biotech is dedicated to bringing new therapeutics to millions of patients suffering from chronic ocular or dermal inflammatory diseases.

OnCusp Therapeutics is a biopharmaceutical company dedicated to accelerating oncology medication innovation globally. It focuses on translating preclinical drug candidates into clinical proof-of-concept stage and advancing them for rapid global early clinical development.

Qihan Biotech is a biomedical company specializing in genetic technology with a focus on addressing the global shortage of organ donors. The company aims to produce safe and effective cells, tissues, and organs for human transplantation using advanced gene editing techniques. By applying these technologies to xenogenic organ transplantation, Qihan Biotech seeks to create organs that can be transplanted into humans, thereby reducing the need for traditional organ transplants and saving lives.

Beijing Yuanxin is a technology company that offers an integrated healthcare platform for pharmaceutical distribution and health insurance.

Wuhan Neurophth Biotechnology Co., Ltd. is a pioneering ophthalmology gene drug research and development company based in Wuhan, China, established in 2008. It focuses on gene therapies for ocular genetic diseases, with a particular emphasis on Leber hereditary optic neuropathy (LHON), a condition caused by genetic mutations. Neurophth has made significant advancements in the field, completing the world's first clinical study of gene therapy for LHON in 2011, which involved nine patients and has since observed their progress over seven years. The company aims to develop effective treatments for various ophthalmic disorders, including degenerative optic nerve injuries and vascular retinopathy, thereby providing physicians with innovative therapeutic options for patients suffering from these conditions.

neoX Biotech is a Beijing-based biotechnology company founded in 2018 that specializes in the development of antigen-based cancer vaccines. By integrating artificial intelligence with biophysics, neoX Biotech focuses on the discovery and development of macromolecular and multispecific drugs, primarily in the field of immuno-oncology. The company has established a platform for early therapeutic discovery, which includes neoantigen prediction and T cell receptor screening, as well as the characterization of protein-protein interactions. This innovative approach aims to provide effective treatments for cancer patients by advancing drug research and development.

Visen Pharmaceuticals is an innovative biopharmaceutical company focused on developing and providing advanced treatments for endocrine diseases in China. With a patient-centric approach, Visen aims to deliver first-in-class or best-in-class products, covering both common and rare endocrine conditions in adults and children. The company leverages cutting-edge technologies and global resources, with established offices in Shanghai, Beijing, Hong Kong, and Taipei, along with a Greater China R&D and manufacturing site in Suzhou.

dMed Company Limited, also known as dMed Biopharmaceutical Co., Ltd., is a clinical contract research organization based in Shanghai, China. Established in 2016, dMed specializes in offering a comprehensive range of services to support the development of medicines and medical devices. Its offerings include consulting, clinical operations, biostatistics and programming, data management, pharmacovigilance, clinical science and medical affairs, quality assurance, and regulatory affairs and strategy. The company serves a diverse clientele, including biopharmaceutical and medical device companies, and aims to establish itself as a prominent international brand in the field of drug innovation services and solutions.

SciNeuro Pharmaceuticals is a biotechnology company based in Shanghai, China, focused on developing innovative medicines for patients with central nervous system (CNS) diseases. The company is committed to transforming the treatment landscape for these conditions through a robust product pipeline that emphasizes internal innovation and global collaboration. SciNeuro's drug development is guided by breakthrough scientific evidence, including insights from human genetics and pharmacology, targeting the underlying mechanisms of CNS diseases. By addressing these pathological mechanisms, SciNeuro aims to provide transformative therapies that not only aim to cure these diseases but also enhance the quality of life for patients.

D3 Bio, established in 2020, is a biotechnology company headquartered in China. It specializes in the development and registration of innovative medicines, primarily focusing on oncology and immunology. The company's approach involves analyzing clinical and market data to identify gaps in current treatments, employing unique drug development methodologies to target new disease areas and routes, and ultimately providing patients with alternative therapeutic options.

EdiGene Inc. is a biotechnology company specializing in the development of genome editing technologies for therapeutic applications in cancer and various genetic diseases. Founded in 2015 and headquartered in Beijing, China, with additional offices in Guangzhou and Cambridge, Massachusetts, EdiGene focuses on both ex vivo and in vivo gene-editing therapies. The company has established proprietary platforms for editing hematopoietic stem cells and T cells, as well as an RNA base editing approach for in vivo applications. EdiGene's innovative methods enable targeted modifications of genetic information in human cells and facilitate high-throughput drug discovery through advanced screening techniques. By translating these technologies into novel therapeutics, EdiGene aims to improve the safety and efficacy of gene therapy, ultimately benefiting patients, the pharmaceutical industry, and the scientific research community.

XtalPi is a pharmaceutical technology company that applies quantum mechanics, artificial intelligence, and high-performance computing to accelerate drug discovery and development. Its Intelligent Digital Drug Discovery and Development platform weaves physics-based modeling with AI to increase efficiency, accuracy, and success rates at critical stages of R&D. The company offers tools for crystal structure prediction and determination, solid-state testing and analysis, and crystallization process development, as well as solid-state screening and evaluation, enabling faster optimization of drug candidates. XtalPi also provides drug design support for small molecules and collaboration options in antibody and peptide research, and offers platform-based AI model development and integration across pharmaceutical workflows. Founded in 2014, it is based in Cambridge, Massachusetts, with additional offices in China.

Dizal Pharmaceutical is a research-driven biotechnology company that specializes in the discovery, development, and commercialization of innovative medicines. The company focuses on creating first-in-class and best-in-class therapeutic solutions, emphasizing the development of groundbreaking drugs. With a commitment to advancing healthcare, Dizal engages in extensive research and development activities, alongside production and sales of its pharmaceutical products. Through its efforts, Dizal aims to contribute significantly to the pharmaceutical industry by delivering effective treatments that address unmet medical needs.

LP Pharmaceuticals (Xiamen) Co., Ltd., located in Xiamen Biomedical Industry Base which formulates and manufactures pharmaceuticals with enhanced delivery properties. The company was founded in 2012 by a group of scientists and business professionals with extensive experience in the US and Chinese pharmaceutical industry. Proprietary delivery platforms include mucosal and oral controlled release. Therapeutic areas currently concern central nervous system, digestive system, cardiovascular, cancer and AIDS.

neoX Biotech is a Beijing-based biotechnology company founded in 2018 that specializes in the development of antigen-based cancer vaccines. By integrating artificial intelligence with biophysics, neoX Biotech focuses on the discovery and development of macromolecular and multispecific drugs, primarily in the field of immuno-oncology. The company has established a platform for early therapeutic discovery, which includes neoantigen prediction and T cell receptor screening, as well as the characterization of protein-protein interactions. This innovative approach aims to provide effective treatments for cancer patients by advancing drug research and development.

Simcha Therapeutics is a biopharmaceutical company focused on developing engineered cytokine immunotherapy for cancer treatment. Founded in 2018 and headquartered in New Haven, Connecticut, the company utilizes directed evolution to create novel cytokines that enhance the immune system's ability to combat diseases. Its lead program, ST-067, is a designer IL-18 cytokine that has demonstrated significant antitumor effects in animal models, both as a standalone treatment and in combination with anti-PD-1 checkpoint inhibitors. This innovative approach aims to provide patients with more effective immunotherapies, thereby improving their ability to fight cancer.

Beijing Yuanxin is a technology company that offers an integrated healthcare platform for pharmaceutical distribution and health insurance.

Buymed operates a digital pharmaceuticals distribution platform in Vietnam, known as Thuocsi.vn. Founded in 2018 and based in Ho Chi Minh City, the platform supplies a wide range of healthcare products, including medicines, cosmetics, medical devices, and supplements. It serves over 1,000 pharmacies and clinics across the country, offering detailed product information such as pricing and active ingredients. Additionally, Thuocsi.vn features a communication network that provides important updates, including product recalls. The company is recognized as a successful startup in the medical technology sector, attracting young talent eager to integrate advanced technology into healthcare solutions.

Wuhan Neurophth Biotechnology Co., Ltd. is a pioneering ophthalmology gene drug research and development company based in Wuhan, China, established in 2008. It focuses on gene therapies for ocular genetic diseases, with a particular emphasis on Leber hereditary optic neuropathy (LHON), a condition caused by genetic mutations. Neurophth has made significant advancements in the field, completing the world's first clinical study of gene therapy for LHON in 2011, which involved nine patients and has since observed their progress over seven years. The company aims to develop effective treatments for various ophthalmic disorders, including degenerative optic nerve injuries and vascular retinopathy, thereby providing physicians with innovative therapeutic options for patients suffering from these conditions.

CERo Therapeutics is a biotechnology company focused on cellular immunotherapy and next-generation engineered T cell therapeutics for cancer. It develops platforms that integrate innate and adaptive immune programs to enhance anti-tumor activity and engage the body's full immune repertoire. The company was incorporated in 2016 and is headquartered in San Francisco, California. Its lead product, CER-1236, is an autologous T-cell therapy targeting a novel tumor antigen, TIM-4 ligand.

Adagene is a clinical-stage biotechnology company focused on developing immuno-oncology antibodies targeting novel epitopes. It employs its proprietary Smart Antibody Technology to enhance success rates, expedite time to market, and reduce development costs for therapeutic antibodies.

Transcenta Holding is a clinical-stage biopharmaceutical company that offers fully integrated capabilities in antibody discovery, research and development, manufacturing, and business development. The company concentrates on developing innovative antibody-based therapeutics for oncology and selected non-oncology indications, including bone and kidney disorders, with a pipeline that includes Osemitamab (TST001), TST002, TST003, TST006, MSB2311, MSB0254, TST808, and other candidates. Headquartered with multiple sites in China—Suzhou, Shanghai, Hangzhou, and Beijing—and with research and development and operations in the United States at Waltham and Princeton, Transcenta operates as a global biotherapeutics business. Founded in 2019, the company aims to advance therapeutic antibodies through discovery, development, and manufacturing to address unmet patient needs. Its business scope encompasses clinical research and trial services alongside its development programs, positioning it to accelerate pipeline progress and collaborate on global opportunities.

ViGeneron develops innovative gene therapies focused on treating ophthalmic diseases with significant unmet medical needs. Its pipeline is built on two proprietary adeno-associated virus (AAV) technology platforms: vgAAV, enabling superior transduction efficiency and less invasive treatment administration, and REVeRT, targeting diseases caused by mutations in large genes.

Shanghai Anovent Pharmaceutical Co., Ltd., founded in 2017 and headquartered in Shanghai, China, specializes in the development of high-quality inhalation medicines tailored for hospitals and medical institutions. The company focuses on offering safe and affordable pharmaceutical products, which include both generic and specialized inhalation therapies. By providing these medications, Anovent aims to enhance the quality of medical treatment available to patients in healthcare settings.

Qihan Biotech is a biomedical company specializing in genetic technology with a focus on addressing the global shortage of organ donors. The company aims to produce safe and effective cells, tissues, and organs for human transplantation using advanced gene editing techniques. By applying these technologies to xenogenic organ transplantation, Qihan Biotech seeks to create organs that can be transplanted into humans, thereby reducing the need for traditional organ transplants and saving lives.

Yaoyanshe, established in 2012 and headquartered in Shanghai, China, operates as a Contract Research Organization (CRO) technology platform. It specializes in providing end-to-end services for pharmaceutical research and development, including clinical monitoring, project management, registration affairs, biostatistics, pharmacovigilance, medical affairs, and Site Management Organization (SMO) services. The company's core offering is an application designed to facilitate value sharing and trading within the industry, empowering patients with up-to-date treatment information and enabling professionals to assess creditworthiness, analyze competition, and evaluate sponsor projects more effectively. Yaoyanshe aims to address key industry challenges and enhance the efficiency of pharmaceutical research and development.

Tencent Trusted Doctors, a company established in early August 2018 upon the merger of Tencent Doctorwork and Trusted Doctors, is acquiring the start-up in an attempt to create a private healthcare network that provides both online and offline services through the so-called "celebrity effect".

Cullgen Inc. is a clinical-stage biopharmaceutical company developing small molecule therapeutics based on its uSMITE platform, which enables targeted protein degradation by using novel E3 ligands to selectively degrade disease-causing proteins. The approach aims to address cancers, inflammatory and autoimmune diseases, and other conditions lacking effective therapies. Founded in 2018 and based in San Diego, Cullgen's pipeline includes degrader programs such as TRK and GSPT1, as well as other candidates like DAC.

Burning Rock Biotech is a cancer diagnostics company that leverages next-generation sequencing and bioinformatics to guide personalized cancer treatment. It develops and provides a portfolio of tissue- and blood-based, NGS-driven therapy selection tests, including OncoScreen Plus, LungPlasma, ColonCore and HRDCore, and evaluates biomarkers such as microsatellite instability, tumor mutation burden, and NTRK fusions across multiple cancer types, including lung, gastrointestinal, prostate, breast, hematologic, thyroid, colorectal, ovarian, pancreatic, and bladder cancers. The company supports clinical and research use through one-stop services spanning genetic testing and companion diagnostic development, operating through central laboratory and in-hospital models. It collaborates with major pharmaceutical companies on clinical trials and research to advance targeted therapies and diagnostics. Founded in 2014, it is headquartered in Guangzhou, with a Guangzhou laboratory and an R&D center in Shanghai, reflecting its focus on expanding access to precision oncology in China.

Beijing Yuanxin is a technology company that offers an integrated healthcare platform for pharmaceutical distribution and health insurance.

BrightGene Bio-Medical Technology Company is a biopharmaceutical firm based in Suzhou, China, specializing in the research, development, manufacturing, and commercialization of innovative medicines and high-quality generic active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs). The company has a diverse product pipeline that includes immuno-oncological agents, GLP-1 receptor agonists for type 2 diabetes, and antibody-drug conjugates aimed at treating solid tumors and brain cancers. Additionally, BrightGene develops a variety of treatments such as Eribulin, Trabectedin, and various macromolecules and cytotoxic payloads. Its product offerings span multiple therapeutic areas, including oncology, cardiology, infectious diseases, and immunology. Founded in 2001, BrightGene has positioned itself as a leader in small molecules and nucleotide drugs, focusing on advancing therapeutics across all stages of development.

Transcenta Holding is a clinical-stage biopharmaceutical company that offers fully integrated capabilities in antibody discovery, research and development, manufacturing, and business development. The company concentrates on developing innovative antibody-based therapeutics for oncology and selected non-oncology indications, including bone and kidney disorders, with a pipeline that includes Osemitamab (TST001), TST002, TST003, TST006, MSB2311, MSB0254, TST808, and other candidates. Headquartered with multiple sites in China—Suzhou, Shanghai, Hangzhou, and Beijing—and with research and development and operations in the United States at Waltham and Princeton, Transcenta operates as a global biotherapeutics business. Founded in 2019, the company aims to advance therapeutic antibodies through discovery, development, and manufacturing to address unmet patient needs. Its business scope encompasses clinical research and trial services alongside its development programs, positioning it to accelerate pipeline progress and collaborate on global opportunities.

Xiaoyaoyao is a comprehensive pharmaceutical circulation field in the era of big data and the Internet As a service provider. Xiaoyaoyao's "Pharmaceutical Help" platform is an e-commerce platform that has been approved by the State Food and Drug Administration and has a B2B drug wholesale license, integrating drug procurement, warehousing, sales, logistics and distribution. , subverting the traditional procurement model of hierarchical distribution. At present, the business has covered more than 20 provinces across the country, with a storage area of ​​nearly 500,000 square meters, serving more than 3,000 suppliers and more than 500,000 pharmacies and clinic end customers across the country.

Beijing Deep Intelligent Pharma Technology Co., Ltd. specializes in leveraging artificial intelligence and blockchain technology to enhance drug discovery, development, and medical affairs for pharmaceutical companies. Founded in 2017 and based in Beijing, the company offers a range of products, including a multi-language medical machine translation engine, intelligent pharmacovigilance for risk management, and tools for creating multilingual educational materials. Deep Intelligent Pharma also provides AI-enabled solutions for medical writing, document review, and quality control, as well as a patient search ecosystem to facilitate medical and clinical research. Additionally, the company offers intelligent regulatory affairs solutions to streamline drug research and development processes. Operating globally, including in China, the United States, and Japan, Deep Intelligent Pharma aims to improve the efficiency and quality of the pharmaceutical development lifecycle.

Qihan Biotech is a biomedical company specializing in genetic technology with a focus on addressing the global shortage of organ donors. The company aims to produce safe and effective cells, tissues, and organs for human transplantation using advanced gene editing techniques. By applying these technologies to xenogenic organ transplantation, Qihan Biotech seeks to create organs that can be transplanted into humans, thereby reducing the need for traditional organ transplants and saving lives.

Farcast Biosciences, established in 2019, is a clinical diagnostic company based in Boston, Massachusetts, with operations in Bangalore, India. The company specializes in developing and utilizing a proprietary Human Tumor Micro Dynamics (HTMD) platform. This platform preserves the natural state of human tumors through the culture of fresh, unmodified tumor fragments, creating a human tumor microenvironment. Farcast's technology enables oncologists to evaluate individual tumors and predict patient response to treatments before initiating therapy. Additionally, it serves drug developers and researchers by providing accurate and precise models for testing and analysis, facilitating the development of personalized cancer therapies.

Eden Biologics is a biopharmaceutical company that focuses on developing biosimilars and providing contract development and manufacturing services to clients and partners in the biopharmaceutical industry. The company specializes in producing complex dosage forms, including oral solids, liquids, semi-solids for both prescription and over-the-counter products, as well as macromolecule biologics. Eden Biologics offers expertise in manufacturing biologics from cell line development through commercial production, with a global and regional regulatory affairs knowledge base to ensure affordability and accessibility of biopharmaceuticals worldwide.

Founded in 2018, Brii Biosciences is a biotechnology company dedicated to researching, developing, and commercializing medicines for chronic illnesses, with a primary focus on infectious diseases. Headquartered in Durham, North Carolina, the company operates additional offices in Shanghai and Beijing, China; and San Francisco, California.

GRAIL focuses on developing technologies for early cancer detection. Founded in 2016, the company specializes in a pan-cancer screening test that measures circulating nucleic acids in blood using high-intensity sequencing.

CStone Pharmaceuticals, founded in 2015, focuses on developing and commercializing innovative immunotherapy and precision treatment drugs for cancer patients worldwide. Its pipeline comprises over a dozen candidates targeting various indications, with immuno-oncology at its core.

Adagene is a clinical-stage biotechnology company focused on developing immuno-oncology antibodies targeting novel epitopes. It employs its proprietary Smart Antibody Technology to enhance success rates, expedite time to market, and reduce development costs for therapeutic antibodies.

Moderna is a biotechnology company focused on messenger RNA therapeutics and vaccines. It develops mRNA-based medicines that instruct cells to produce therapeutic proteins or antibodies in vivo, targeting infectious diseases, oncology, cardiovascular diseases, and rare genetic disorders. Founded in 2010 and headquartered in Cambridge, Massachusetts, the company has built a broad pipeline with multiple development candidates across several modalities and a track record highlighted by a COVID-19 vaccine authorized in the United States. Moderna collaborates with major pharmaceutical and research partners, including AstraZeneca, Merck, Vertex, and Alexion, as well as academic institutions such as Harvard University and Karolinska Institutet. It maintains manufacturing collaborations with Lonza for mRNA production and Catalent for fill-finish, and engages with public sector and philanthropic supporters such as BARDA, DARPA, and the Gates Foundation. As of 2025, the company continued expanding its mRNA development program across infectious disease, oncology, cardiovascular, and rare genetic diseases.

XtalPi is a pharmaceutical technology company that applies quantum mechanics, artificial intelligence, and high-performance computing to accelerate drug discovery and development. Its Intelligent Digital Drug Discovery and Development platform weaves physics-based modeling with AI to increase efficiency, accuracy, and success rates at critical stages of R&D. The company offers tools for crystal structure prediction and determination, solid-state testing and analysis, and crystallization process development, as well as solid-state screening and evaluation, enabling faster optimization of drug candidates. XtalPi also provides drug design support for small molecules and collaboration options in antibody and peptide research, and offers platform-based AI model development and integration across pharmaceutical workflows. Founded in 2014, it is based in Cambridge, Massachusetts, with additional offices in China.

Burning Rock Biotech is a cancer diagnostics company that leverages next-generation sequencing and bioinformatics to guide personalized cancer treatment. It develops and provides a portfolio of tissue- and blood-based, NGS-driven therapy selection tests, including OncoScreen Plus, LungPlasma, ColonCore and HRDCore, and evaluates biomarkers such as microsatellite instability, tumor mutation burden, and NTRK fusions across multiple cancer types, including lung, gastrointestinal, prostate, breast, hematologic, thyroid, colorectal, ovarian, pancreatic, and bladder cancers. The company supports clinical and research use through one-stop services spanning genetic testing and companion diagnostic development, operating through central laboratory and in-hospital models. It collaborates with major pharmaceutical companies on clinical trials and research to advance targeted therapies and diagnostics. Founded in 2014, it is headquartered in Guangzhou, with a Guangzhou laboratory and an R&D center in Shanghai, reflecting its focus on expanding access to precision oncology in China.

Farcast Biosciences, established in 2019, is a clinical diagnostic company based in Boston, Massachusetts, with operations in Bangalore, India. The company specializes in developing and utilizing a proprietary Human Tumor Micro Dynamics (HTMD) platform. This platform preserves the natural state of human tumors through the culture of fresh, unmodified tumor fragments, creating a human tumor microenvironment. Farcast's technology enables oncologists to evaluate individual tumors and predict patient response to treatments before initiating therapy. Additionally, it serves drug developers and researchers by providing accurate and precise models for testing and analysis, facilitating the development of personalized cancer therapies.

Health 724 is a health service provider based on users, health managers, and health products. They offer direct supply of health products to users who are concerned about their own and their families' health, as well as customized health solutions.

Shanghai MOLBASE Technology Co., Ltd. is a prominent player in the chemical e-commerce sector, offering a comprehensive platform that connects buyers and vendors of chemicals. Founded in 2011 and headquartered in Shanghai, the company provides a robust compound database and e-commerce solutions tailored for the pharmaceutical, biotech, specialty industries, and research organizations. MOLBASE enables professional buyers to inquire about and purchase a wide range of chemicals through a centralized website that features real-time product data updates. The platform leverages artificial intelligence technologies to enhance its services, which include business intelligence, financing information, and logistics facilitation. Recognized as the largest chemical e-commerce platform in China by gross merchandise value in 2017 and 2018, MOLBASE continues to serve as an integrated resource for chemical transactions and related services globally.

Zai Lab is a biopharmaceutical company dedicated to discovering and developing transformative medicines for cancer, autoimmune, and infectious diseases. Founded in Shanghai in 2014, the company focuses on bringing innovative therapies to patients worldwide. Zai Lab's pipeline includes proprietary drug candidates such as Niraparib, Optune, Ripretinib, and Margetuximab, among others. The company collaborates with global biopharma leaders to expand its pipeline and foster innovation in China.

Life Infinity is a health management company dedicated to providing personalized health services aimed at age-specific diagnosis, treatment, and disease prevention. The company focuses on systematic management of chronic diseases, delaying the effects of aging, and relieving symptoms associated with various health conditions. Additionally, Life Infinity offers specialized services in health regeneration, anti-aging medical treatments, and natural healing programs, enabling clients to access professional regenerative medicine services tailored to individual needs.

Founded in 2015, Orasis Pharmaceuticals specializes in developing corrective eye drops for treating presbyopia. Its lead product, CSF-1, improves near visual acuity by pupil modulation, eliminating the need for reading glasses.

Baheal Pharmaceutical Group is a pharmaceutical commercialization platform that specializes in providing comprehensive marketing services for pharmaceutical product manufacturers. The company offers a range of services, including health brand marketing promotion, wholesale distribution of pharmaceuticals, and retail services. By focusing on these key areas, Baheal aims to enhance the market presence of its clients and facilitate the distribution of pharmaceutical products.

Life Infinity is a health management company dedicated to providing personalized health services aimed at age-specific diagnosis, treatment, and disease prevention. The company focuses on systematic management of chronic diseases, delaying the effects of aging, and relieving symptoms associated with various health conditions. Additionally, Life Infinity offers specialized services in health regeneration, anti-aging medical treatments, and natural healing programs, enabling clients to access professional regenerative medicine services tailored to individual needs.

Founded in 2001, Celon Laboratories is a Hyderabad-based pharmaceutical company specializing in the development, manufacturing, and marketing of niche therapy products. Its portfolio includes oncology and critical care products, available in various dosage forms, serving markets across Asia Pacific, Africa, Latin America, CIS countries, and Eastern Europe.

Akumentis Healthcare Ltd, founded in 2010 and based in Thane, India, is a prominent manufacturer of pharmaceutical products specializing in branded generics. The company holds a strong market position in various therapeutic areas, particularly in women's health, and offers a diverse range of healthcare solutions aimed at addressing challenging medical conditions. Its product portfolio includes treatments for anti-infections, infertility, gynecology, musculo-skeletal issues, gastroenterology, orthopedics, and dermatology, among others. As a subsidiary of Akums Drugs and Pharmaceuticals Ltd, Akumentis Healthcare is dedicated to delivering effective healthcare products that cater to specific needs in the market.

Burning Rock Biotech is a cancer diagnostics company that leverages next-generation sequencing and bioinformatics to guide personalized cancer treatment. It develops and provides a portfolio of tissue- and blood-based, NGS-driven therapy selection tests, including OncoScreen Plus, LungPlasma, ColonCore and HRDCore, and evaluates biomarkers such as microsatellite instability, tumor mutation burden, and NTRK fusions across multiple cancer types, including lung, gastrointestinal, prostate, breast, hematologic, thyroid, colorectal, ovarian, pancreatic, and bladder cancers. The company supports clinical and research use through one-stop services spanning genetic testing and companion diagnostic development, operating through central laboratory and in-hospital models. It collaborates with major pharmaceutical companies on clinical trials and research to advance targeted therapies and diagnostics. Founded in 2014, it is headquartered in Guangzhou, with a Guangzhou laboratory and an R&D center in Shanghai, reflecting its focus on expanding access to precision oncology in China.

Tencent Trusted Doctors, a company established in early August 2018 upon the merger of Tencent Doctorwork and Trusted Doctors, is acquiring the start-up in an attempt to create a private healthcare network that provides both online and offline services through the so-called "celebrity effect".

La Renon is a healthcare company dedicated to providing high-quality pharmaceutical products and services aimed at addressing critical illnesses and chronic diseases. Founded by a team of experienced professionals from various sectors of the healthcare industry, the company focuses on treating a wide range of conditions, including nephrology, neurological disorders, critical care, gynecology, orthopedics, gastroenterology, urology, respiratory issues, and cardio-metabolic diseases. La Renon emphasizes continuous value addition to its business model, striving to create a unique platform that benefits all stakeholders involved. The company aims to enhance the capabilities of healthcare professionals, ultimately improving patient outcomes and quality of life.

Zai Lab is a biopharmaceutical company dedicated to discovering and developing transformative medicines for cancer, autoimmune, and infectious diseases. Founded in Shanghai in 2014, the company focuses on bringing innovative therapies to patients worldwide. Zai Lab's pipeline includes proprietary drug candidates such as Niraparib, Optune, Ripretinib, and Margetuximab, among others. The company collaborates with global biopharma leaders to expand its pipeline and foster innovation in China.

Zai Lab is a biopharmaceutical company dedicated to discovering and developing transformative medicines for cancer, autoimmune, and infectious diseases. Founded in Shanghai in 2014, the company focuses on bringing innovative therapies to patients worldwide. Zai Lab's pipeline includes proprietary drug candidates such as Niraparib, Optune, Ripretinib, and Margetuximab, among others. The company collaborates with global biopharma leaders to expand its pipeline and foster innovation in China.

Tencent Trusted Doctors, a company established in early August 2018 upon the merger of Tencent Doctorwork and Trusted Doctors, is acquiring the start-up in an attempt to create a private healthcare network that provides both online and offline services through the so-called "celebrity effect".

Zhangshang Yaodian is a pharmacy app that provides safe medication services.

Angel Group Holding Company, founded in 2008 and based in Chengdu, China, focuses on integrating high-quality medical resources and managing healthcare brands. The company employs a development strategy centered on scale, branding, and professionalism, gradually expanding its services and investments into various interventional medical fields. Notably, its flagship facility, Angel Maternity Hospital, has garnered recognition as a leading maternity hospital in China, receiving awards for its reputation and quality of care. This hospital is distinguished as the first in China and the only one in the southwest region to achieve accreditation from the Joint Commission International. Angel Group is committed to a comprehensive approach that encompasses medical treatment, research, prevention, care, and rehabilitation, while maintaining a modern management structure and a skilled team of physicians. The company aims to adhere to international standards in healthcare management, continually seeking to enhance its operations and expand its presence within the mainland Chinese healthcare market.